Clatterbridge Cancer Centre Papillon+ Training a Strong Success

/in , , /by

28th March 2026
Clatterbridge Cancer Centre Papillon+ Training a Strong Success
The Liner Hotel, Liverpool | 25th–26th March 2026

The first of two Papillon+ training events scheduled for 2026 was successfully delivered at The Liner Hotel, hosted by Arthur Sun Myint and Jean Pierre Gérard.

The two-day event welcomed clinicians and specialists from across Great Britain and North America, reflecting the growing international interest in Papillon+ technology.

Momentum has continued to build following the National Institute for Health and Care Excellence (NICE) approval on 13th November 2025. NICE now recommends Contact X-ray Brachytherapy (CXB) for selected lower rectal cancer patients, including operable cases with tumours up to T3a–b. These updated guidelines represent a significant step forward, offering more patients the opportunity for organ preservation and non-invasive treatment options.

A key focus of the training was the OPERA Trial, alongside wider discussion on the evolving “watch and wait” approach in rectal cancer management.

The event also benefited from multidisciplinary input, with valuable contributions from surgical teams, radiation oncology specialists, and medical physics professionals.

With both clinical outcomes and healthcare economics under increasing scrutiny, Papillon+ is continuing to establish itself as a credible alternative to conventional surgery—particularly in improving post-treatment quality of life.

Following NICE approval, momentum in the UK continues to accelerate. Several clinical trials are now in the pipeline, with an additional 8–10 installations expected across treatment centres of excellence by the end of 2026.

Clatterbridge Papillon+ Training Conference Successfully Delivered

/in , , /by

25-26th March 2026
Clatterbridge Papillon+ Training Conference Successfully Delivered

The first of two Papillon+ training conferences scheduled for 2026 was successfully delivered on 25th–26th March, bringing together clinicians from across the UK and North America.

Hosted by Arthur Sun Myint and Jean Pierre Gérard, the two-day event provided a structured programme focused on clinical practice, collaboration, and knowledge sharing.

Attendees benefited from a range of expert-led sessions, alongside valuable discussions around the continued development and application of Papillon+ technology in clinical settings.

The event highlighted the growing international interest in non-invasive treatment approaches and reinforced the importance of shared learning in advancing patient care.

Leading Advocate of Papillon Technology Presents at HSJ Cancer Forum

/in , , /by

13th March 2026

Arthur Sun Myint, one of the leading advocates of Papillon technology, recently presented at the HSJ Cancer Forum, contributing to discussions on the progression of innovation into everyday clinical practice.

Drawing on decades of experience in the development and application of Papillon therapy, Professor Myint shared insights on how advancements in treatment are translating into real-world benefits for patients. His presentation highlighted the importance of bridging the gap between early-stage innovation and widespread clinical adoption.

The session reinforced the growing role of non-invasive treatment options in cancer care and the importance of continued collaboration across the healthcare sector to support improved patient outcomes.

🔗 Read the full article here:
https://www.linkedin.com/pulse/from-innovation-pilots-practice-professor-arthur-sun-myintobpse